Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
| 2.55 | |
| 2.52 | |
| - | |
| 2.74 | |
| 2.5 | |
| 1.01-7.42 | |
| 59 225 K | |
| 21 615 K | |
| 0 | |
| -0.86 | |
| 2.221 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
A downtrend has been apparent in Aileron Therapeutics, Inc. (ALRN) lately. While the stock has lost 10.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in ...
Shares of Aileron Therapeutics, Inc. (ALRN) have been struggling lately and have lost 21% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean t...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
